The Effect of 0.12% Unoprostone Isopropyl (Rescula) on Intraocular Pressure in Normotensive Dogs

Ron Ofri, Dorit Raz, Philip H Kass, George N. Lambrou, Christine L. Percicot

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Rescula (0.12% unoprostone isopropyl) is the first docosanoid compound approved for treatment of glaucoma in humans. It is commercially available in Japan, and is undergoing clinical testing elsewhere. The aim of this study was to evaluate the effect of Rescula on intraocular pressure (IOP) in normotensive dogs. After establishing a baseline diurnal IOP curve, six dogs were unilaterally treated with Rescula while the contralateral eye was treated with a placebo. Applanation tonometry was performed in both eyes, and pupil size was evaluated, 30 min after treatment, and at 1-hr intervals for the next 9 hr. Rescula caused a significant (p=0.014) and long-lasting decrease in IOP, from 20.49 ± 2.02 mm Hg in control eyes to 15.49 ± 0.69 mm Hg in treated eyes. These results suggest that Rescula is potentially efficacious in treatment of canine glaucoma.

Original languageEnglish (US)
Pages (from-to)1313-1315
Number of pages3
JournalJournal of Veterinary Medical Science
Volume62
Issue number12
StatePublished - Dec 2000

Keywords

  • Canine
  • Glaucoma
  • Unoprostone isopropyl

ASJC Scopus subject areas

  • Marketing
  • veterinary(all)

Fingerprint Dive into the research topics of 'The Effect of 0.12% Unoprostone Isopropyl (Rescula) on Intraocular Pressure in Normotensive Dogs'. Together they form a unique fingerprint.

  • Cite this